10x Genomics (TXG) Misses Q2 EPS by 22c

10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.57), $0.22 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $114.6 million versus the consensus estimate of $117.64 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $500-520 million, versus the consensus of $571 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• 10X Genomics (TXG) PT Raised to $42 at Piper Sandler
• Lucid reports Q2 output, names new CFO and five other leaders
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform